Natural cytotoxic activity against cytomegalovirus-infected target cells following marrow transplantation

Transplantation. 1987 Oct;44(4):504-8. doi: 10.1097/00007890-198710000-00009.

Abstract

Forty-five patients at high risk for cytomegalovirus (CMV) infection were studied during the first 100 days after marrow transplant to determine the relationship between cytotoxicity against CMV-infected HLA-mismatched target cells and CMV infection. Peripheral blood lymphocytes (PBL) from 35 patients who developed CMV infection had significantly lower cytotoxicity against CMV-infected targets 20-40 days transplant compared with PBL from normal controls (P = 0.003). Responses by PBL from 10 uninfected transplant recipients were not significantly decreased. The PBL that lysed CMV targets had phenotypic and E-rosetting characteristics consistent with natural killer cells. Cytotoxicity against CMV-infected targets by PBL from patients with acute graft-versus-host disease (GVHD) was reduced 20-40 days after transplant compared with responses by patients without GVHD (P = 0.04). Survival from CMV infection was longer in patients whose PBL had greater than or equal to 15% lysis of CMV-infected targets during the first 20-60 days after transplant (P = 0.04). This study suggests that natural cytotoxicity of CMV targets is an important correlate of the acquisition and outcome of CMV infection after marrow transplant.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Viral / analysis
  • Bone Marrow Transplantation*
  • Cells, Cultured
  • Cytomegalovirus / immunology*
  • Cytomegalovirus Infections / etiology*
  • Cytomegalovirus Infections / immunology
  • Cytotoxicity Tests, Immunologic
  • Cytotoxicity, Immunologic*
  • Fibroblasts
  • Graft vs Host Disease / complications
  • Graft vs Host Disease / immunology
  • Humans
  • Immunity, Innate
  • Immunosuppression Therapy / adverse effects*
  • Killer Cells, Natural / immunology*
  • Postoperative Complications / etiology*
  • Postoperative Complications / immunology
  • Risk
  • Virus Activation

Substances

  • Antibodies, Viral